Aarkstore Market Research Report - Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

Submitted by: Submitted by

Views: 52

Words: 2232

Pages: 9

Category: Science and Technology

Date Submitted: 02/13/2015 03:20 AM

Report This Essay

Aarkstore Market Research Report - Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

Browse Full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/81464/type-2-diabetes-therapeutics-in-asia-pacific-markets

Published: Nov 2014 | 107 Pages

Discounted Market Research Reports available on Aarkstore.com Offer valid till 28th February, 2015

For more inquiries, contact at +91 9987295242 / 022-27564953

Email: enquiry@aarkstore.com

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth”, which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts.

In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China.

Scope

The report analyzes the treatment use...